0.38
+0.0167(+4.54%)
Currency In USD
| Previous Close | 0.37 |
| Open | 0.38 |
| Day High | 0.39 |
| Day Low | 0.35 |
| 52-Week High | 2.53 |
| 52-Week Low | 0.24 |
| Volume | 516,696 |
| Average Volume | 606,724 |
| Market Cap | 22.57M |
| PE | -0.35 |
| EPS | -1.1 |
| Moving Average 50 Days | 0.39 |
| Moving Average 200 Days | 0.66 |
| Change | 0.02 |
If you invested $1000 in BioAtla, Inc. (BCAB) since IPO date, it would be worth $12.39 as of August 18, 2025 at a share price of $0.384. Whereas If you bought $1000 worth of BioAtla, Inc. (BCAB) shares 3 years ago, it would be worth $37.8 as of August 18, 2025 at a share price of $0.384.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025
GlobeNewswire Inc.
Aug 04, 2025 12:00 PM GMT
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, toda
BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting
GlobeNewswire Inc.
Jul 17, 2025 12:00 PM GMT
SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company” or “BioAtla”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the tr
BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress
GlobeNewswire Inc.
Jul 03, 2025 12:00 PM GMT
Adverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions in heavily pretreated adenocarcinoma patients Dose escalation now continuing at 1.2 mg weekly by